Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
Provided herein are polypeptides that include one or more β-tricalcium phosphate (βTCP)-binding sequence(s) and uses thereof.
1. A method of delivering a therapeutic agent to bone or cartilage in a subject, the method comprising delivering to the bone or cartilage a chimeric polypeptide comprising the therapeutic agent and one or more binding polypeptides, wherein the one or more binding polypeptides comprise: (a) a sequence at least 80% identical to SEQ ID NO: 2 (VIGESTHHRPWS), (b) a sequence at least 80% identical to SEQ ID NO: 4 (ILAESTHHKPWT), (c) a sequence at least 80% identical to SEQ ID NO: 6 (IIGESSHHKPFT), (d) a sequence at least 80% identical to SEQ ID NO: 7 (GLGDTTHHRPWG), or (e) a combination comprising two or more sequences of (a)-(d).
2. The method of claim 1 , wherein the chimeric polypeptide is bound to a scaffold via the one or more binding peptides.
3. The method of claim 2 , wherein the scaffold comprises calcium phosphate.
4. The method of claim 3 , wherein the scaffold comprises β-tricalcium phosphate.
5. The method of claim 2 , wherein the scaffold comprises a ceramic.
6. The method of claim 2 , wherein the scaffold comprises hydroxyapatite.
7. The method of claim 2 , wherein the scaffold comprises bioactive glass.
8. The method of claim 2 , wherein the scaffold comprises a powder, a putty, a paste, a mesh, or a sponge, or a combination of two or more thereof.
9. The method of claim 1 , wherein the subject comprises a bone defect, and a therapeutically effective amount of the chimeric polypeptide is delivered to promote bone formation and/or bone repair.
10. The method of claim 9 , wherein the bone defect is caused by an infection, a tumor, a trauma, an adverse event to treatment, or a combination of two or more thereof.
11. The method of claim 1 , wherein the subject comprises a bone fracture, and a therapeutically effective amount of the chimeric polypeptide is delivered to treat the bone fracture.
12. The method of claim 1 , wherein the subject comprises bone loss, and a therapeutically effective amount of the chimeric polypeptide is delivered to treat the bone loss.
13. The method of claim 1 , wherein the subject comprises a cartilage defect, and a therapeutically effective amount of the chimeric polypeptide is delivered to promote cartilage formation and/or cartilage repair.
14. The method of claim 13 , wherein the cartilage defect is caused by a disease, osteochondritis, osteonecrosis, or trauma, or a combination of two or more thereof.
15. The method of claim 1 , wherein the one or more binding peptides comprises SEQ ID NO: 2.
16. The method of claim 1 , wherein the one or more binding peptides comprises SEQ ID NO: 4.
17. The method of claim 1 , wherein the one or more binding peptides comprises SEQ ID NO: 6.
18. The method of claim 1 , wherein the one or more binding peptides comprises SEQ ID NO: 7.
19. The method of claim 1 , wherein the one or more binding peptides further comprises a sequence at least 80% identical to SEQ ID NO: 1 (LLADTTHHRPWT).
20. The method of claim 1 , wherein the one or more binding peptides further comprises SEQ ID NO: 1 (LLADTTHHRPWT).